ASARINA PHARMA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.95 SEK | +6.50% |
|
+5.56% | +7.95% |
| 02-27 | Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 21.03M 229M 1.68B |
|---|---|---|---|---|---|
| Net income 2021 | -31M -338M -2.47B | Net income 2022 | -13M -142M -1.04B | EV / Sales 2021 | - |
| Net cash position 2021 | 16.42M 179M 1.31B | Net cash position 2022 | 13.58M 148M 1.08B | EV / Sales 2022 | - |
| P/E ratio 2021 |
-1.15
x | P/E ratio 2022 |
-1.31
x | Employees | 1 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.98% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +6.50% | ||
| 1 week | +5.56% | ||
| Current month | +5.56% | ||
| 1 month | -3.06% | ||
| 3 months | -20.17% | ||
| 6 months | +27.01% | ||
| Current year | +7.95% |
1 week
0.85
0.95
1 month
0.841.09
Current year
0.801.32
1 year
0.601.55
3 years
0.6010.20
5 years
0.6048.00
10 years
0.6048.00
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Nordkild
CEO | Chief Executive Officer | 69 | 31/12/15 |
| Director of Finance/CFO | 69 | 31/03/17 | |
| Public Communications Contact | 62 | 31/12/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul de Potocki
CHM | Chairman | 62 | 31/12/17 |
| Public Communications Contact | 62 | 31/12/10 | |
Marianne Kock
BRD | Director/Board Member | 69 | 31/12/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.95 | +6.50% | 49 |
| 26/04/24 | 0.892 | -6.11% | 3,318 |
| 25/04/24 | 0.95 | 0.00% | 22,785 |
| 24/04/24 | 0.95 | +1.50% | 1,768 |
| 23/04/24 | 0.936 | +4.00% | 22,999 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 10:22 am
More quotes
Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of womenâs health. The Companyâs main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Companyâs main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.
Calendar
20/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +7.95% | 1.84M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.38% | 22.15B | |
| -17.37% | 21.02B | |
| -8.77% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ASAP Stock
